𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HIV-1 integrase inhibitors: 2007–2008 update

✍ Scribed by Kavya Ramkumar; Erik Serrao; Srinivas Odde; Nouri Neamati

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
892 KB
Volume
30
Category
Article
ISSN
0198-6325

No coin nor oath required. For personal study only.

✦ Synopsis

In recent years, HIV-1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the advent of a new generation of antiretroviral drugs. The development of raltegravir and other successful lead IN inhibitors has also influenced the IN inhibitor design strategy. This has led to the identification of several potent inhibitors in these last two years. Further, an increased understanding of IN structural biology has opened up novel approaches to inhibiting IN, such as targeting its multimerization or interaction with cellular cofactors. This review covers recent developments in the field of IN inhibitor design from 2007 to 2008.

📜 SIMILAR VOLUMES

HIV-1 integrase inhibitors: 2003–2004 up
HIV-1 integrase inhibitors: 2003–2004 update
✍ Raveendra Dayam; Jinxia Deng; Nouri Neamati 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 906 KB

## Abstract The integration of viral cDNA into the host genome is an essential step in the HIV‐1‐life cycle and is mediated by the virally encoded enzyme, integrase (IN). Inhibition of this process provides an attractive strategy for antiviral drug design. The discovery of β‐diketo acid inhibitors

HIV-1 integrase inhibitors: 2005–2006 up
HIV-1 integrase inhibitors: 2005–2006 update
✍ Raveendra Dayam; Rambabu Gundla; Laith Q. Al-Mawsawi; Nouri Neamati 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 813 KB

## Abstract HIV‐1 integrase (IN) catalyzes the integration of proviral DNA into the host genome, an essential step for viral replication. Inhibition of IN catalytic activity provides an attractive strategy for antiretroviral drug design. Currently two IN inhibitors, MK‐0518 and GS‐9137, are in adva

Synthesis of New Potential HIV-1 Integra
Synthesis of New Potential HIV-1 Integrase Inhibitors.
✍ Stefania Ferro; Angela Rao; Maria Zappala; Alba Chimirri; Maria Letizia Barreca; 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 19 KB 👁 2 views

## Abstract For Abstract see ChemInform Abstract in Full Text.